Arachidonic acid

Arachidonic Acid Market to increase by USD 114.82 million between 2023 to 2028; Rising awareness about preventative healthcare boosts the market - Technavio

Retrieved on: 
Thursday, December 7, 2023

NEW YORK, Dec. 7, 2023 /PRNewswire/ -- The arachidonic acid market size is expected to grow by USD 114.82 million from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 7, 2023 /PRNewswire/ -- The arachidonic acid market size is expected to grow by USD 114.82 million from 2023 to 2028.
  • In addition, the growth momentum of the market will progress at a CAGR of  7.23% during the forecast period, according to Technavio.
  • Rising awareness about preventative healthcare is notably driving the arachidonic acid market.
  • However, factors such as the availability of substitutes for arachidonic acid may impede market growth.

CABIO unveils NeoHMOs™ series at FIE 2023, targeting growing global demand for infant formula

Retrieved on: 
Thursday, November 30, 2023

At the FIE 2023, CABIO unveiled a wide range of products -- arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc. as well as the NeoHMOs™ family, including 2'-Fucosyllactose (2'-FL), 3-Fucosyllactose (3'-FL), lacto-N-tetraose (LNT), lacto-N-neo-tetraose (LNnT), 3'-sialic lactose (3'-SL), and 6'-sialic lactose (6'-SL).

Key Points: 
  • Over the past 26 years, cumulative visitor count of the prestigious Fi Europe has surpassed 500,000 person/times.
  • This year, CABIO unveiled an exciting new product range, NeoHMOs™, at the FIE 2023.
  • At the FIE 2023, CABIO unveiled a wide range of products -- arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc.
  • Our vision is to become a global leader in biotechnology, empowering and enriching lives through nutrition and health.

CABIO unveils NeoHMOs™ series at FIE 2023, targeting growing global demand for infant formula

Retrieved on: 
Thursday, November 30, 2023

At the FIE 2023, CABIO unveiled a wide range of products -- arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc. as well as the NeoHMOs™ family, including 2'-Fucosyllactose (2'-FL), 3-Fucosyllactose (3'-FL), lacto-N-tetraose (LNT), lacto-N-neo-tetraose (LNnT), 3'-sialic lactose (3'-SL), and 6'-sialic lactose (6'-SL).

Key Points: 
  • Over the past 26 years, cumulative visitor count of the prestigious Fi Europe has surpassed 500,000 person/times.
  • This year, CABIO unveiled an exciting new product range, NeoHMOs™, at the FIE 2023.
  • At the FIE 2023, CABIO unveiled a wide range of products -- arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc.
  • Our vision is to become a global leader in biotechnology, empowering and enriching lives through nutrition and health.

Global Nutritional Lipids Market Analysis Report 2023-2030: Seizing Growth Opportunities in the Krill Oil-based Omega-3 Fatty Acids Market - ResearchAndMarkets.com

Retrieved on: 
Friday, October 6, 2023

The "Global Nutritional Lipids Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nutritional Lipids Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • In this comprehensive research service, our analyst presents a thorough analysis of nutritional lipid ingredients, encompassing omega-3 fatty acids, medium chain triglycerides (MCT), omega-6 (arachidonic acid or ARA) fatty acids, and phytosterols, both qualitatively and quantitatively.
  • In 2022, North America emerged as the dominant region in terms of nutritional lipid demand.
  • Furthermore, the evolving landscape of consumer preferences is fostering advancements in the delivery formats of nutritional lipid supplements.

Journal of Pharmaceutical Analysis Studies Make Advances in Spatiotemporal Pharmacometabolomics, Plasma Proteome Profiling, and Hepatocellular Carcinoma Therapeutics

Retrieved on: 
Thursday, July 27, 2023

Drug-induced hepatotoxicity is routinely assessed during drug screening, which involves the use of two-dimensional (2D) monolayers of hepatocytes.

Key Points: 
  • Drug-induced hepatotoxicity is routinely assessed during drug screening, which involves the use of two-dimensional (2D) monolayers of hepatocytes.
  • We coupled airflow-assisted desorption electrospray ionization-MSI with 3D HepG2 spheroids to assess the metabolism and hepatotoxicity of amiodarone (AMI)."
  • Researchers show how NaY, a newly synthesized zeolite adsorbs and traps proteins from blood plasma, thus forming a protein corona or layer.
  • The third study focuses on the potential treatment of hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths globally.

Global Arachidonic Acid Market Analysis Report 2022: A $300+ Million Market by 2030 - Rising Demand for Applications Including Infant Formula and Supplements - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 15, 2022

The "Arachidonic Acid Market Size, Share & Trends Analysis Report by Form (Solid, Solvent), by Source (Plant, Animal), by Application (Infant Formula, Supplement), by Region (EU, APAC), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Arachidonic Acid Market Size, Share & Trends Analysis Report by Form (Solid, Solvent), by Source (Plant, Animal), by Application (Infant Formula, Supplement), by Region (EU, APAC), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global arachidonic acid market is expected to reach USD 309.0 million by 2030, registering a CAGR of 4.3%
    The growth is majorly driven by the rising demand for applications including infant formula and supplements.
  • The growing need for essential minerals in baby food is likely to create demand for ARA-based infant formula across the globe over the forecast period.
  • The introduction of technologies, such as particle size reduction and microencapsulation techniques, are expected to boost the industry growth in the coming years

Groundbreaking Study Finds C15:0, an Emerging Essential Fatty Acid, is Key to Unlocking the Second-Ever Discovered Full-Acting Endogenous Cannabinoid

Retrieved on: 
Tuesday, August 23, 2022

SAN DIEGO, Aug. 23, 2022 /PRNewswire-PRWeb/ -- A recently published peer-reviewed study in Nature's Scientific Reports revealed that an emerging essential fatty acid, called C15:0, is used by our bodies to make the second-ever discovered full-acting endocannabinoid.

Key Points: 
  • SAN DIEGO, Aug. 23, 2022 /PRNewswire-PRWeb/ -- A recently published peer-reviewed study in Nature's Scientific Reports revealed that an emerging essential fatty acid, called C15:0, is used by our bodies to make the second-ever discovered full-acting endocannabinoid.
  • In this groundbreaking study funded by the Office of Naval Research, pentadecanoylcarnitine (PDC) was identified as a key molecule that is made within our bodies' cells by combining C15:0 with carnitine.
  • At least two studies have associated higher circulating C15:0 to longer lifespan , and a second team corroborated odd-chain saturated fatty acids, including C15:0, as essential fatty acids .
  • Seraphina Therapeutics, Inc. is a health and wellness company dedicated to advancing global health through the discovery of essential fatty acids and micronutrient therapeutics.

MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

Retrieved on: 
Tuesday, August 9, 2022

This subgroup analysis was conducted based on in-vitro research findings that MN-001 down regulated CD36 mRNA and upregulated ABCG1 mRNA.

Key Points: 
  • This subgroup analysis was conducted based on in-vitro research findings that MN-001 down regulated CD36 mRNA and upregulated ABCG1 mRNA.
  • NAFLD is considered the hepatic manifestation of metabolic syndrome; studies have reported that 50% of patients with metabolic syndrome also have NAFLD.
  • The presence of dyslipidemia (hypercholesterolemia, hypertriglyceridemia, or both) is reported in 20 - 80% of NAFLD cases.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.

MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

Retrieved on: 
Tuesday, July 26, 2022

Kazuko Matsuda, MD, PhD, Chief Medical Officer of MediciNova, Inc., commented, "We are very pleased that this Phase 2 trial evaluating MN-001 has commenced.

Key Points: 
  • Kazuko Matsuda, MD, PhD, Chief Medical Officer of MediciNova, Inc., commented, "We are very pleased that this Phase 2 trial evaluating MN-001 has commenced.
  • MN-001 appears to reduce serum lipid profiles in patients with a dual diagnosis of NAFLD and T2DM/prediabetes with dyslipidemia.
  • This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MN-001 (tipelukast) in patients with NAFLD, T2DM and hypertriglyceridemia.
  • The design of the Phase 2 clinical trial includes the following elements:
    Approximately 40 male and female patients, ages 21 to 75 years, in the U.S.

MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan

Retrieved on: 
Thursday, June 23, 2022

It has also been observed to reduce serum triglyceride levels for patients with high serum triglycerides in multiple clinical trials conducted previously.

Key Points: 
  • It has also been observed to reduce serum triglyceride levels for patients with high serum triglycerides in multiple clinical trials conducted previously.
  • Furthermore, the improvements in the serum lipid profile were more significant in the patients with type 2 diabetes/prediabetes.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.
  • MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.